- GlobeNewswire•5 days agoSunesis Pharmaceuticals Announces Presentation of Updated Results from the VALOR Trial Examining Overall Survival in Patients Age 60 Years and Older with Relapsed/Refractory AML at the ASH Annual Meeting
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2016-- Sunesis Pharmaceuticals, Inc. today announced the presentation of updated results from the VALOR trial examining overall survival in patients age 60 years and ...
- GlobeNewswire•5 days agoSunesis Pharmaceuticals Announces Presentation of Results from Completed Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK inhibitor SNS-062 at ASH Annual Meeting
Program On Track to Begin Dosing in Phase 1 B/2 Study of Patients with B-Cell Malignancies in the First Half of 2017. SOUTH SAN FRANCISCO, Calif., Dec. 05, 2016-- Sunesis Pharmaceuticals, Inc. today announced ...
- Associated Press•last month
The South San Francisco, California-based company said it had a loss of 62 cents per share. The biopharmaceutical company posted revenue of $610,000 in the period. The company's shares closed at $3.64. ...
SNSS : Summary for Sunesis Pharmaceuticals, Inc. - Yahoo Finance
Sunesis Pharmaceuticals, Inc. (SNSS)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||2.14 x 100|
|Ask||4.89 x 500|
|Day's Range||3.71 - 3.98|
|52 Week Range||2.64 - 6.30|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.32|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|